KOSDAQBiotech & Pharma174900

AbClon

₩24,650▲ 2.07%2026-11-18 close
Market Cap
₩491.8B
Turnover
₩6.8B
Volume
270K
Shares out.
20M
PER
—
PBR
8.5×
EPS
-₩896
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

AbClon: Licensed Phase 3 Progress Versus Four Years of Operating Losses

AbClon's licensed gastric cancer drug HLX22 is in a global Phase 3 trial, while the DART filings show operating losses in each of the four years from 2022 to 2025 even though 2025 revenue rose sharply.

  1. 1

    2025 revenue was KRW 4.71 billion, up 101.5% year on year, but the operating loss widened to KRW 17.6 billion in the same year.

  2. 2

    The core asset is HLX22 (AC101), developed by partner Henlius, which is enrolling 550 patients in a global Phase 3 trial and targets commercialization in 2028.

  3. 3

    Attributable net losses over the last four quarters total KRW 17.7 billion, and the company has posted losses in five consecutive quarters through the third quarter of 2026.

  4. 4

    The debt ratio fell to 17.1% at the end of 2025 from 63.9% in 2024, and total equity stands at KRW 60.4 billion.

  5. 5

    On November 13, 2026, news of a partner hiring for US regulatory work and a European patent registration for AT101 coincided with a sharp intraday rise in the share price.

02

Business structure

AbClon is an antibody drug developer that discovers candidates on its own platforms and then licenses them to overseas partners. The company describes its NEST and MAT platforms as the basis for its in-house antibody pipeline.

Its 2026 state-funded R&D covered novel epitopes, a CD19-targeted CAR-T and diffuse large B-cell lymphoma. The core pipeline has three parts. AC101, a HER2-targeted gastric cancer antibody known globally as HLX22, was licensed to Henlius, and its clinical programs have grown to nine within about a year.

AT101, a CD19 CAR-T candidate, is covered by a commercialization agreement signed in March 2025 with TCT Health Technology in Turkey. AM105 is a bispecific antibody built on the AffiMab platform, and its core technology has been registered as a domestic patent.

Deal terms combine upfront payments, milestones and royalties on net sales. According to a brokerage report, the Henlius deal has already delivered USD 11.5 million, with sales milestones of up to USD 42 million. Key counterparties are overseas partners such as Henlius and TCT.

The benchmark in CAR-T remains the approved products. A January 2026 report said AT101's interim figures exceed those of Kymriah and Yescarta, but it was based on 32 evaluable patients.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.6B-₩3.5B−225.9%
2025Q4₩1.6B-₩5B−308.4%
2026Q1₩400M-₩3.1B−704.5%
2026Q2₩1.7B-₩6.3B−371.4%
2026Q3₩1.8B-₩3.9B−219.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩3.4B-₩8.7B-₩9.3B−256.9%−25.3%47.7%
2023₩2.9B-₩11.6B-₩12.9B−404.8%−47.4%66.9%
2024₩2.3B-₩15.6B-₩16.3B−666.2%−55.4%63.9%
2025₩4.7B-₩17.6B-₩17.9B−374.1%−29.6%17.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a DART-filed basis, revenue was KRW 3.41 billion in 2022, KRW 2.88 billion in 2023 (down 15.5% year on year) and KRW 2.34 billion in 2024 (down 18.7%), before rebounding to KRW 4.71 billion in 2025 (up 101.5%). Among the years from 2022 to 2025, 2025 was the largest and 2024 the smallest.

Operating losses were KRW 8.75 billion in 2022, KRW 11.6 billion in 2023, KRW 15.6 billion in 2024 and KRW 17.6 billion in 2025, with the losses widening each year. Operating margins were -256.9% in 2022, -404.8% in 2023, -666.2% in 2024 and -374.1% in 2025.

The 2025 margin improved mainly because the revenue base grew sharply, while the absolute loss still increased.

Attributable net losses were KRW 9.25 billion, KRW 12.9 billion, KRW 16.3 billion and KRW 17.9 billion from 2022 to 2025, and the filings report total net loss including non-controlling interests at the same levels.

On a quarterly basis, revenue was KRW 1.57 billion in the third quarter of 2025 and KRW 1.62 billion in the fourth quarter, fell to KRW 434 million in the first quarter of 2026, then rose to KRW 1.68 billion in the second quarter and KRW 1.77 billion in the third quarter (up 12.9% year on year).

Operating losses were KRW 3.54 billion, KRW 5.01 billion, KRW 3.06 billion, KRW 6.25 billion and KRW 3.89 billion across the same five quarters, so losses were largest in the second quarter of 2026, the quarter of the revenue rebound. The filings do not explain the cause of the swings.

Whether licensing fee timing drove them is an inference, not a filed fact. Operating cash outflows were KRW 7.49 billion in 2022, KRW 9.48 billion in 2023, KRW 14.4 billion in 2024 and KRW 13.8 billion in 2025.

05

Industry analysis

The antibody drug market that AbClon operates in is centered on licensing. When partners expand clinical spending, licensors earn milestones and royalties. A Chinese brokerage report on Henlius pointed to late-stage anticancer drugs as a new growth driver.

For HLX22, the report cited high progression-free survival in a Phase 2 trial but said the final efficacy and safety need confirmation in a large Phase 3 study. In CAR-T, approved products such as Kymriah, Yescarta and Breyanzi serve as the reference points.

AT101 is in Phase 2 in Korea, and its Turkish partnership widens the overseas route to approval. The company says more than 10,000 people a year die of blood cancer in Turkey, which suggests meaningful treatment demand.

Compared with other licensing-focused listed peers such as LigaChem Biosciences and ABL Bio, AbClon's development stage and partner structure differ. Because its R&D spending is large relative to revenue, a return to profitability depends heavily on when its pipeline reaches commercialization.

06

Outlook

The most important milestone is the global Phase 3 trial of HLX22. Partner Henlius is running a global Phase 3 in metastatic gastric cancer, and first dosing has been completed in Korea, China, Japan, the United States, Europe, Australia and Latin America. The trial plans to enroll 550 patients in total.

In the long-term Phase 2 follow-up, median progression-free survival has not been reached in the combination arm, and the company and partner say progression risk is 80% lower than the 8.3-month control arm. That is Phase 2 data, so the final efficacy must be confirmed in Phase 3.

A brokerage report expects the main trial results in 2027. The partner targets commercialization in 2028, according to AbClon.

Expectations around a US marketing application are rising, and news of a partner hiring US regulatory staff was cited as a driver of the November 13, 2026 share price jump, but this is an expectation rather than a company announcement of a filing.

AM105 has entered primate toxicology testing at a partner's request, and the company aims to use the data for a global licensing deal.

In the Turkish AT101 agreement, the upfront payment is due within 60 days of signing and milestones are paid within 30 days of IND approval, with TCT bearing all commercialization costs. AbClon expects the expansion of AC101 trials to broaden royalty opportunities.

Whether these expectations translate into revenue can be checked in the disclosure of revenue composition in the next annual report.

07

Valuation

PER
—
PBR
8.5×
ROE
-45.0%
EPS
-₩896
BPS
₩2,705
Dividend per share
₩0

Because attributable net losses have continued over the last four quarters, the price-to-earnings ratio cannot be calculated. Earnings-based multiples therefore offer limited comparison. On an asset basis, the share price sits in a high premium zone relative to net asset value.

A high price-to-book ratio means the market is pricing future returns from the pipeline rather than current book assets. The company pays no dividend, so its dividend yield is effectively zero.

Total equity at the end of 2025 is entirely attributable to controlling shareholders, and liabilities are KRW 10.3 billion, which gives a relatively solid balance sheet. Operating cash outflows of KRW 13.8 billion in 2025 continue, so the pace at which equity is consumed is a key variable.

The share price reacts sharply to pipeline news. On November 13, 2026, a partner hiring report and a patent registration coincided with an intraday surge, and a January 2026 report noted that a large one-year gain had drawn an investment warning.

Valuation therefore depends more on clinical results and the timing of licensing receipts than on earnings multiples.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Global Phase 3 under way and Phase 2 data

HLX22 is in a 550-patient global Phase 3 trial running across several regions at once. The company and partner reported that median progression-free survival in the combination arm has not been reached, and that progression risk is 80% lower than in the 8.3-month control arm. These are company-reported figures and have not been independently verified.

Upfront and royalty structure of the licensing deals

A brokerage report says the Henlius deal has already delivered USD 11.5 million, with sales milestones of up to USD 42 million. After commercialization, royalties of 3% to 5% depend on sales levels.

Because partners bear much of the development cost, the model places a relatively smaller funding burden on AbClon itself.

Platform patents and follow-on assets

Domestic patent registration for the core technology of AM105 is complete, and filings cover seven major countries and regions. Reports say AT101 (Nespessel) has completed a core European patent registration. AC101's clinical programs have grown to nine within a year, widening the room for indication expansion.

09

Bear factors

Operating losses for four straight years and widening losses

The operating loss grew each year, from KRW 8.75 billion in 2022 to KRW 17.6 billion in 2025. The attributable net loss also widened to KRW 17.9 billion in 2025.

Losses have continued for five consecutive quarters through the third quarter of 2026, and attributable net losses over the last four quarters total KRW 17.7 billion.

Large swings in quarterly revenue

Revenue fell to KRW 434 million in the first quarter of 2026 and then rose 287.9% to KRW 1.68 billion in the second quarter. The operating loss was largest in the same second quarter, at KRW 6.25 billion. If revenue moves with the timing of licensing receipts, quarterly results are harder to forecast.

Small samples behind the clinical evidence

AT101's interim figures were based on only 32 evaluable patients, and reports noted that averages could fall as enrollment grows. HLX22's Phase 2 results still need Phase 3 confirmation, so a trial setback could reduce the value of the licensing deals.

10

Risk factors

Clinical and regulatory risk

If the global Phase 3 trial for HLX22 fails to reproduce the Phase 2 results, expectations for milestones and royalties under the licensing deals could fall. A brokerage report also noted that final efficacy and safety must be confirmed in a large Phase 3 study. US approval expectations come from press reports rather than an official company announcement.

Funding and financial risk

Operating cash outflow stood at KRW 13.8 billion in 2025, and losses have continued. Total equity of KRW 60.4 billion is fully attributable to controlling shareholders, and losses over the last four quarters total KRW 17.7 billion, so the rate at which equity is consumed matters. The debt ratio is low at 17.1% in 2025, but continued cash outflows make funding plans more important.

Partner dependence and share price volatility

Control of clinical timing and commercialization for major assets rests with partners such as Henlius and TCT. The timing of royalty receipts can also shift with partners' development decisions.

The share price has moved sharply in short periods on pipeline news, and a January 2026 report mentioned an investment warning.

11

What to watch next

  1. Late March 2027

    The 2026 annual report. It shows full-year revenue and operating loss and reveals whether fourth-quarter revenue reflects one-time licensing items.

  2. During 2027

    Main results of the HLX22 global Phase 3 trial. A brokerage expects readout in 2027, and whether the progression-free survival benefit holds in Phase 3 is the key variable for the licensing value.

  3. Mid-May 2027

    The Q1 2027 quarterly report. It shows whether revenue keeps growing after the first-quarter 2026 drop and whether the operating loss narrows.

  4. Mid-2028

    The partner's target for commercialization in metastatic gastric cancer. Once approved and sold, sales milestones and royalties would begin to accrue.

12

Overall view

AbClon uses its in-house antibody platform to create candidates and licenses them to overseas partners. Its core asset, HLX22, is in a 550-patient global Phase 3 trial across several regions, and the partner targets commercialization in 2028. A brokerage report expects the main trial results in 2027.

Financially, the debt ratio fell to 17.1% at the end of 2025, and total equity stands at KRW 60.4 billion. However, operating losses have persisted for four consecutive years from 2022 to 2025, and the company has recorded losses for five consecutive quarters through the third quarter of 2026.

Revenue rose to KRW 4.71 billion in 2025, but quarterly revenue is volatile, dropping sharply in the first quarter of 2026 before recovering. The share price sits in a high premium zone relative to net asset value, and the price-to-earnings ratio cannot be calculated.

The next points to confirm are the revenue composition in the 2026 annual report, the HLX22 Phase 3 results, and the partner's commercialization timeline.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. saramin.co.kr
  2. thevc.kr
  3. hankyung.com
  4. kind.krx.co.kr
  5. v.daum.net
  6. m.irgo.co.kr
  7. saramin.co.kr
  8. file.alphasquare.co.kr
  9. job-post.co.kr
  10. etoday.co.kr
  11. hankyung.com
  12. etoday.co.kr
  13. thebionews.net
  14. sedaily.com
  15. etoday.co.kr
  16. newspim.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis